The US and UK tout a trade agreement鈥攚ith a few caveats: The proposal would offer the UK some tariff relief while giving US businesses access to a $5 billion market opportunity, but it鈥檚 not a done deal.
Gilead joins pharma companies that are boosting US manufacturing amid Trump-induced challenges: Gilead Sciences faces unique challenges as a leading HIV drugmaker鈥擳rump鈥檚 tariff threats coincide with cuts to global HIV programs and LGBTQ+ healthcare initiatives.
Spending on prescription drugs in the US grew 11.4% last year: IQVIA projects spending to keep increasing through 2029. Lowering Rx costs is emerging as a key priority for the Trump admin鈥攎uch to the dismay of pharma.
Trump asks regulators to make it easier to build US drug manufacturing sites: Drugmakers should wait for the precise tariff rate on the sector鈥攕et to come within two weeks鈥攂efore investing in more domestic infrastructure.
Hugo Boss is adjusting to the macro landscape on the fly: The German fashion house is rerouting China-made goods to other markets and stockpiling in the US to blunt the impact of tariffs.